BMRA (Biomerica) Risk Assessment

View and export this data going back to 1978. Start your Free Trial

What is Biomerica Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Biomerica is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Biomerica's Risk Assessment

For the Medical Devices subindustry, Biomerica's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomerica's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Biomerica's Risk Assessment falls into.

Biomerica (NAS:BMRA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Biomerica Risk Assessment Related Terms

Thank you for viewing the detailed overview of Biomerica's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomerica Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

17571 Von Karman Avenue, Irvine, CA, USA, 92614

Website

https://www.biomerica.com

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

Executives

John P. Kenny	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani	director, officer: Cheif Executive Officer	17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu	officer: Chief Financial Officer	12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri	director
Catherine Coste	director	966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan	officer: Chief Financial Officer	114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo	director	C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano	director	11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio	officer: President-diagnostics	1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore	director, 10 percent owner, officer: Secretary	1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson	director	1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider	other: Greater than 5% holder	4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The	other: Greater than 5% holder	7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm	director	1533 MONROVIA AVE., NEWPORT BEACH CA 92663